Pressure BioSciences launches contract service business for biopharma market

14-Jan-2019 - Last updated on 14-Jan-2019 at 15:38 GMT

(Image:Getty/gordenkoff)

Pressure BioSciences has launched a commercial biopharmaceutical contract service business after acquiring a protein therapeutics platform that it says reduces challenges and manufacturing costs of the growing drug market.

Pressure BioSciences (PBI) in December 2017 acquired the assets of BaroFold, including the company’s high-pressure protein disaggregation and refolding platform, PreEMT.

Now, the company has announced the commercial launch of its biopharmaceutical contract services business, which will leverage the BaroFold platform for protein therapeutic candidate manufacturing.

PBI is currently working with its first client, a publicly-traded biopharma company.

Bradford Young, chief commercial officer of PBI said in a statement, “The early results were so encouraging in helping our client surmount difficult manufacturing challenges in the production of their protein therapeutic drug candidate, that they have now asked us to extend our Barofold work to include two additional protein drug candidates.”

Currently, more than 200 therapeutic proteins and peptides are approved for clinical use in the US and are becoming a growing part of the global healthcare industry. In May of 2016, it was forecasted that the global protein drug market will grow to $248bn by 2020.

Protein therapeutics are often more potent and specific in their effectiveness for diseases like cancer and auto-immune disorders.